CCW702 / AbbVie, Scripps Research Institute - LARVOL DELTA

CBR-CCW702-3001: First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=22 | Terminated | Sponsor: Calibr, a division of Scripps Research | Trial completion date: Dec 2023 ➔ Oct 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2023 ➔ Oct 2022; Business decision

Metastases • Trial completion date • Trial primary completion date • Trial termination • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

CBR-CCW702-3001: First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=22 | Active, not recruiting | Sponsor: Calibr, a division of Scripps Research | Recruiting ➔ Active, not recruiting | N=70 ➔ 22

Enrollment change • Enrollment closed • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

[VIRTUAL] Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC). (ASCO 2021) - P1 | "This study will enroll 20-30 patients in Part 1 and approximately 40 patients in Part 2 . The study opened in December 2019 and is currently enrolling in the dose escalation phase."

Clinical • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. (PubMed, Sci Adv) - P1 | "In cynomolgus monkeys, CCW702 was well tolerated up to 34.1 mg/kg per dose, with near-complete subcutaneous bioavailability and a PK profile supporting testing of a weekly dosing regimen in patients. CCW702 is being evaluated in a first in-human clinical trial for men with mCRPC who had progressed on prior therapies (NCT04077021)."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

CCW702: Proof-of-concept data from P1 (NCT04077021) trial for mCRPC in 2022 (AbbVie, 39th Annual J.P. Morgan Healthcare Conference (Virtual Meeting))

P1 data • Oncology • Prostate Cancer

CCW702: Proof-of-concept data from P1 (NCT04077021) trial for mCRPC in 2022 (AbbVie, 39th Annual J.P. Morgan Healthcare Conference (Virtual Meeting))

P1 data • Oncology • Prostate Cancer

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Calibr, a division of Scripps Research; Initiation date: Mar 2020 ➔ Jun 2020

Clinical • Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Calibr, a division of Scripps Research; Not yet recruiting ➔ Recruiting; Initiation date: Oct 2019 ➔ Jan 2020

Clinical • Enrollment open • Trial initiation date

Newly added product (clinicaltrials.gov) - P1, Prostate Cancer

Pipeline update